FORMATION OF LYMPHATIC VESSELS MEDIATED BY PROTEINS Slit AND ROUNDABOUNT (Robo), AND ITS APPLICATION

摘要

1. A method of preventing or treating a disorder mediated by a Slit protein, comprising: administering to a subject a therapeutically effective amount of an agent that modulates or prevents interactions between the Slit protein and Robo protein, where the disorder includes the formation of lymphatic vessels. The method of claim 1, wherein the Slit protein is Slit2.3. The method of claim 1, wherein the Robo protein is Robo1 or Robo4.4. The method of claim 1, wherein the agent is an anti-Slit protein antibody. The method of claim 1, wherein the agent is an anti-Robo protein antibody. The method of claim 4 or 5, wherein the antibody is a monoclonal antibody. The method of claim 6, wherein the antibody is a humanized antibody. The method of claim 1, wherein the agent is a fragment of the extracellular domain of a Robo protein. The method of claim 8, wherein the fragment is derived from a first immunoglobulin-like domain of a Robo protein. The method of claim 1, wherein the agent is a fused Robo protein. The method of claim 10, wherein the Robo protein fusion is a Robo protein Fc.12 fusion. A composition for the prophylaxis or treatment of a disorder mediated by a Slit protein, comprising: an agent that can modulate or inhibit the interaction between the Slit protein and Robo protein; and a pharmaceutically acceptable excipient, carrier, or vehicle, wherein the disorder includes the formation of lymphatic vessels. The composition of claim 12, wherein the Slit protein is Slit2.14. The composition of claim 12, wherein the agent is an antibody to a Slit protein or to a Robo protein. The composition of claim 14, wherein the antibody is a monoclonal antibody. The composition of claim 15, wherein the antibody is a humanized anti